LP-128

N/A

Report date: 2024/12/30 15:49:21
NME

Base Information

Drug NameLP-128
Drug Alias NameLP-128NWP-1080
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHBsAg inhibitors
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Lupeng Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou Lupeng Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A